Suppression of depleted uranium-induced neoplastic transformation of human cells by the phenyl fatty acid, phenyl acetate: Chemoprevention by targeting the p21RAS protein pathway

Radiation Research

Volumn 155, Issue 1, 2001, Pages 163-170

  Miller, Alexandra C ^a,b   Xu, Jiaquan ^a   Stewart, Michael ^a   McClain, David ^a  

^a ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^b AFRRI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HRAS PROTEIN, HUMAN; NICKEL; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PROTEIN P21; URANIUM DERIVATIVE; URANIUM OXIDE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BONE TUMOR; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OSTEOBLAST; OSTEOSARCOMA; RADIATION EXPOSURE;

ANIMALS; ANTICARCINOGENIC AGENTS; BONE NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE; MICE, NUDE; NICKEL; OSTEOBLASTS; OSTEOSARCOMA; PHENYLACETATES; PROTO-ONCOGENE PROTEINS P21(RAS); URANIUM COMPOUNDS;

EID: 0035218644     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2001)155[0163:SODUIN]2.0.CO;2     Document Type: Article

References (31)

1. National Research Council, Committee on the Biological Effects of Ionizing Radiation, Health Risks of Radon and Other Internally Deposited Alpha Emitters (BEIR IV). National Academy Press, Washington, DC, 1988.
2. M. E. Danesi, Kinetic Energy Penetrator Long Term Strategy Study (Abridged). U.S. Army Armament Munitions and Chemical Command - AMCCOM, Picatinny Arsenal, Picatinny, NJ, 1990.
3. X. Lin and M. Costa, Transformation of human osteoblasts to anchorage-independent growth by insoluble nickel particles. Environ. Health Perspect. 102, 289-229 (1994).
4. A. S. Rani, D. Qu, M. K. Sidhu, F. Panagakos, V. Shah, K. M. Klein, N. Brown, S. Pathak and S. Kumar, Transformation of immortal, non-tumorigenic osteoblast-like human osteosarcoma cells to the tumorigenic phenotype by nickel sulfate. Carcinogenesis 14, 947-953 (1993).
5. J. S. Rhim, D. K. Par, P. Arnstein, R. J. Huebner, F. K. Weisburger and W. A. Nelson-Rees, Transformation of human cells in culture by N-methyl-N′-nitro-N-nitrosoguanidine. Nature 256, 751-753 (1975).
6. ras isoprenylation. Int. J. Cancer 53, 302-307 (1993).
7. A. C. Miller, W. F. Blakely, D. Livengood, T. Whittaker, J. Xu, J. W. Ejnik, M. M. Hamilton, E. Parlette, T. St. John and H. Hsu, Depleted uranium-uranyl transformation of human osteoblast cells to the tumorigenic phenotype by depleted uranium chloride. Environ. Health Perspect. 106, 465-471 (1998).
8. A. C. Miller, A. F. Fuciarelli, W. E. Jackson, E. J. Ejnik, C. Emond, S. Strocko, J. Hogan, N. Page and T. Pellmar, Urinary and serum mutagenicity studies with rats implanted with depleted uranium or tantalum pellets. Mutagenicity 13, 643-648 (1998).
9. P. Prasanna, S. Shack, V. Wilson and D. Samid, Phenylacetate in chemoprevention: In vitro and in vivo suppression of 5-aza-2′-deoxycytidine-induced carcinogenesis. Clin. Cancer Res. 1, 865-871 (1995).
10. A. Thibault, M. R. Cooper, W. D. Figg, D. J. Venzon, A. O. Sartor, A. C. Tompkins, M. S. Weinberger, D. J. Headlee, N. A. McCall and D. Samid, A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 54, 1690-1694 (1994).
11. D. Samid, S. Shack and L. T. Sherman, Phenylacetate: A novel non-toxic inducer of tumor cell differentiation. Cancer Res. 52, 1988-1992 (1992).
12. D. Samid, A. Yeh and P. Prasanna, Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80, 1576-1581 (1992).
13. D. Samid, S. Shack and C. E. Myers, Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91, 2288-2295 (1993).
14. D. Samid, Z. Ram, W. R. Hudgins, S. Shack, L. Liu, S. Walbridge and E. H. Oldfield, Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain ketonuria. Cancer Res. 54, 891-895 (1994).
15. C. A. Reznikoff, J. Bertram, D. W. Brankow and C. Heidelberger, Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division. Cancer Res. 33, 3239-3249 (1973).
16. IARC/NCI/EPA Working Group, Cellular and molecular mechanisms of cell transformation and standardization of transforming assays of established cell lines for the prediction of carcinogenic chemicals: Overview and recommended protocols. Cancer Res. 45, 2395-2399 (1985).
17. C. K. Hill, F. M. Buonaguro, C. P. Myers, A. Han and M. M. Elkind, Fission-spectrum neutrons at reduced dose rates enhance neoplastic transformation. Nature 298, 67-69 (1982).
18. J. L. Humm, A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int. J. Radiat. Biol. Oncol. Phys. 13, 1767-1777 (1987).
19. A. Thibault, D. Samid, M. R. Cooper, W. D. Figg, A. C. Tompkins, N. Patronas, D. J. Headlee, D. R. Kohler, D. J. Venzon and C. E. Myers, Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75, 2932-2938 (1995).
20. I. B. Weinstein, Cancer prevention: Recent progress and future opportunities. Cancer Res. 51, 5080-5085 (1991).
21. G. J. Kelloff, C. W. Boone, W. F. Malone and V. E. Steele, Chemoprevention clinical trials. Mutat. Res. 267, 291-295 (1992).
22. T. Pineau, R. W. Hudgins and D. Samid, Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. 52, 659-667 (1996).
23. M. Gorospe, Up-regulation and functional role of p21Waf/Cip1 during growth arrest of human breast carcinoma MCF7 cells by phenylacetate. Cell Growth Differ. 7, 1609-1615 (1996).
24. L. Adam, M. Crepin and L. Israel, Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF7-ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res. 57, 1023-1029 (1997).
25. L. Liu, A. C. Miller and D. Samid, Transcriptional up-regulation of TGF alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine 7, 449-456 (1995).
26. A. C. Miller, T. Whittaker, A. Thibault and D. Samid, Modulation of radiation response of human tumor cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int. J. Radiat. Biol. 72, 211-218 (1997).
27. S. Shack, A. C. Miller and D. Samid, Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res. 2, 865-872 (1996).
28. M. Saito, N. Tanaka, Y. Ohkawa and N. Inui, Inhibition of 12-O-tetradecanoylphorbol-13-acetate-enhanced transformation in vitro by radical scavengers. Cancer Lett. 35, 167-171 (1987).
29. K. Komatsu, Y. Mitsuda, M. Mine and Y. Okumura, Inhibitory effects of Rooibos tea on X-ray-induced C3H10T1/2 cell transformation. Cancer Lett. 77, 33-38 (1994).
30. A. C. Miller, Depleted uranium health effects: Involvement of reactive oxygen intermediates. In Metal Ions in Biology and Medicine. John Libbey Eurotext, Paris, in press.
31. H. G. Claycamp and D. Luo, Plutonium-catalyzed oxidative DNA damage in the absence of significant alpha-particle decay. Radiat. Res. 137, 114-117 (1994).